title: Inhibitor development in two cousins receiving full-length factor VIII (FVIII) and FVIII-Fc fusion protein.
authors: Division of Hematology/Oncology, University of Pittsburgh, Pittsburgh, PA, USA. ragni@dom.pitt.edu.|Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA. ragni@dom.pitt.edu.
authors: M V
authors: MV
authors: Ragni
authors: Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA.
authors: M
authors: M
authors: Alabek
authors: Hemophilia Center of Western Pennsylvania, Pittsburgh, PA, USA.|Division of Pediatric Hematology, Children's Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh, PA, USA.
authors: L M
authors: LM
authors: Malec
mesh_terms: D057134:Antibodies, Neutralizing / Q000097:blood*; D002675:Child, Preschool; D003029:Coagulants / Q000627:therapeutic use*; D005169:Factor VIII / Q000235:genetics* / Q000276:immunology / Q000378:metabolism / Q000627:therapeutic use; D015942:Factor VIIa / Q000627:therapeutic use; D006467:Hemophilia A / Q000188:drug therapy* / Q000473:pathology; D006470:Hemorrhage / Q000517:prevention & control; D006801:Humans; D011994:Recombinant Proteins / Q000627:therapeutic use; D012720:Severity of Illness Index
chemical_list: D057134:Antibodies, Neutralizing; D003029:Coagulants; D011994:Recombinant Proteins; C427184:recombinant factor VIII SQ; D005169:Factor VIII; C103587:recombinant FVIIa; D015942:Factor VIIa